- As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskWhen signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.BioSpace · 1h ago↗ source
- Virginia federal judge says FDA should reconsider mifepristone restrictionsAt a time when the federal government is evaluating restrictions on medication abortion, a federal judge determined that the last administration imposed too many. A Virginia federal judge ordered…Endpoints · 11h ago↗ source
- The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysAs drugmakers prepare for the looming biopharma patent cliff, 2026 has so far been a year for dealmaking. Now, contract manufacturers need to broaden their services to keep up, Fujifilm Biotechnolo…